- Datum05.06.2025
- Uhrzeit08:55 - 18:30 Uhr
- Veranstalter
stock3
stock3, Smartbroker, Vontobel, justTRADE
Moderatoren
Sage Therapeutics Inc. Aktie
Verkaufen
Kaufen
Sage Therapeutics Inc. Chart
Sage Therapeutics Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
1,13 %
Intraday
2,68 %
1 Woche
-8,29 %
1 Monat
23,30 %
Seit Jahresbeginn
-39,74 %
1 Jahr
-81,87 %
3 Jahre
-81,40 %
5 Jahre
-91,11 %
10 Jahre
Passender Service zu Sage Therapeutics Inc.
Webinar zu Sage Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)4,620-13,470
- Jahrestief / Hoch ($)5,401-8,810
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Sage Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Sage Therapeutics Inc.
- Aug5Sage Therapeutics Inc.Q2 2025 Earnings Release
- Nov11Sage Therapeutics Inc.Q3 2025 Earnings Release
- Feb18Sage Therapeutics Inc.Q4 2025 Earnings Release
Beschreibung
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, treatment resistant disorders, generalized anxiety disorders, and bipolar depression; and SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
